PL439306A1 - Liposomowy preparat cynku i miedzi oraz sposób jego wytwarzania - Google Patents
Liposomowy preparat cynku i miedzi oraz sposób jego wytwarzaniaInfo
- Publication number
- PL439306A1 PL439306A1 PL439306A PL43930621A PL439306A1 PL 439306 A1 PL439306 A1 PL 439306A1 PL 439306 A PL439306 A PL 439306A PL 43930621 A PL43930621 A PL 43930621A PL 439306 A1 PL439306 A1 PL 439306A1
- Authority
- PL
- Poland
- Prior art keywords
- zinc
- copper
- lecithin
- preparation
- preparing
- Prior art date
Links
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title abstract 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract 3
- 229910052802 copper Inorganic materials 0.000 title abstract 3
- 239000010949 copper Substances 0.000 title abstract 3
- 229910052725 zinc Inorganic materials 0.000 title abstract 3
- 239000011701 zinc Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 4
- 229940067606 lecithin Drugs 0.000 abstract 4
- 235000010445 lecithin Nutrition 0.000 abstract 4
- 239000000787 lecithin Substances 0.000 abstract 4
- 229920001202 Inulin Polymers 0.000 abstract 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 2
- 229940029339 inulin Drugs 0.000 abstract 2
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 150000001879 copper Chemical class 0.000 abstract 1
- 239000007902 hard capsule Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000003751 zinc Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem zgłoszenia jest liposomowy preparat cynku i miedzi w postaci proszku, w którym dwuwarstwa lipidowa zwiera lecytynę, który zawiera inulinę jako stabilizator preparatu, przy czym stosunek wagowy soli cynku do lecytyny wynosi 1:100, stosunek wagowy soli miedzi do lecytyny wynosi 1:100, natomiast stosunek wagowy lecytyny do inuliny mieści się w zakresie od 1:0,1 do 1:5. Wynalazek dostarcza również kapsułkę twardą zawierającą preparat cynku i miedzi według wynalazku oraz sposób jego wytwarzania.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL439306A PL246287B1 (pl) | 2021-10-25 | Liposomowy preparat cynku i miedzi oraz sposób jego wytwarzania |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL439306A PL246287B1 (pl) | 2021-10-25 | Liposomowy preparat cynku i miedzi oraz sposób jego wytwarzania |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL439306A1 true PL439306A1 (pl) | 2023-05-02 |
| PL246287B1 PL246287B1 (pl) | 2024-12-30 |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL247542B1 (pl) * | 2023-06-26 | 2025-07-21 | Formeds Spolka Z Ograniczona Odpowiedzialnoscia | Preparat zawierający witaminę K2, twarda dojelitowa kapsułka zawierająca preparat witaminy K2 oraz sposób jego wytwarzania |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL247542B1 (pl) * | 2023-06-26 | 2025-07-21 | Formeds Spolka Z Ograniczona Odpowiedzialnoscia | Preparat zawierający witaminę K2, twarda dojelitowa kapsułka zawierająca preparat witaminy K2 oraz sposób jego wytwarzania |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| WO2015011633A8 (en) | Compositions and methods for delivering messenger rna | |
| MX2013002603A (es) | Composicion de aceite y metodo para producir la misma. | |
| EA201300038A1 (ru) | Порошкообразные пищевые жиры | |
| EA200601897A1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина | |
| WO2021050759A3 (en) | Compositions comprising subsets of milk lipids, and methods for producing the same | |
| MX2016005238A (es) | Formulaciones de lipidos para la administracion de acido ribonucleico mensajero. | |
| MX366099B (es) | Deposito de fosfolipidos. | |
| CO6561822A2 (es) | Emulsiones nutricionales que comprenden hmb de calcio y proteinas soluble | |
| WO2012117385A3 (en) | Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it | |
| SA520420064B1 (ar) | Kras مركبات تتضمن متوالية متحولة ودهون واستخداماتها | |
| WO2018217894A8 (en) | FLUORINATED MARKED HALICHONDRIN DERIVATIVES AND METHODS OF SYNTHESIS THEREOF | |
| MX2022004735A (es) | Composiciones que comprenden compuestos superfinos y su produccion. | |
| PH12018501644A1 (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| PH12019500153A1 (en) | Method for processing fat-based flavour concentrate | |
| TN2014000152A1 (en) | Sustained-release preparation | |
| EA202091340A1 (ru) | Способ получения соединений "лекарственное средство-линкер" | |
| PL439126A1 (pl) | Preparat witaminy B12 oraz sposób jego wytwarzania | |
| JP2015036367A5 (pl) | ||
| PL442904A1 (pl) | Preparat zawierający glutation, twarda dojelitowa kapsułka zawierająca preparat glutationu oraz sposób jego wytwarzania | |
| WO2013085422A3 (ru) | Противотуберкулезная композиция и способ ее получения | |
| MY192902A (en) | Umami taste enhancing agent | |
| PL440166A1 (pl) | Preparat witaminy B kompleks, twarda dojelitowa kapsułka żelowa zawierająca preparat witaminowy oraz sposób jego wytwarzania |